Neuralstem, Inc. (CUR) Stock: Here’s What’s Happening

0

Neuralstem, Inc. (CUR) is falling in the market today. The company, one that is focused on the biotech sector, is currently priced at $1.52 after heading down -16.94% so far in today’s session. When it comes to biotech companies, there are several aspects that have the ability to generate price movement in the market. One of the most common is news. Here are the recent trending headlines relating to CUR:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-31-19 11:00AM Seneca Biopharma to Begin Trading Under New Ticker Symbol SNCA
Oct-30-19 07:00AM Seneca Biopharma and QYuns Therapeutics Sign Term Sheet for Global Licensing of Novel Monoclonal Antibodies for Treating Auto-Immune Diseases
Oct-29-19 02:28PM Local biopharma rebrands as part of commercialization strategy
01:17AM Seneca Biopharma to Present at the 7th China Renaissance Healthcare and Life Sciences Leadership Summit
Oct-28-19 11:24PM Seneca Biopharma to Present at the 7th China Renaissance Healthcare and Life Sciences Leadership Summit

However, any time investors are making a decision with regard to investing, investors should take a look at much more than news, this is especially the case in the generally speculative biotech sector. Here’s what’s happening with Neuralstem, Inc..

How CUR Has Been Trending

While a move toward the top in a single session, like the move that we’re seeing from Neuralstem, Inc. may lead to fear in some investors, a single session move by itself should not be the basis of a decision to, or not to, invest in a stock. It’s always important to look into trends experienced by the stock just a single session. As it relates to CUR, below are the movements that investors have seen:

  • Past 5 Sessions – Over the past 7 days, CUR has generated a change in value in the amount of 15.15%.
  • Past Month – The performance from Neuralstem, Inc. in the past 30 days has been -5.00%.
  • Past Three Months – Throughout the past 3 months, the company has produced a ROI that works out to -30.28%
  • Bi-Annually – In the last 6 months, investors have seen a performance that works out to -85.44% from the company.
  • This Year So Far – Since the the last trading session of last year CUR has produced a return on investment of -75.73%.
  • Annually – Lastly, over the last full year, we have seen movement amounting to -86.79% from CUR. Throughout this period, the stock has traded at a high of -88.97% and a low of 38.18%.

Ratios Worth Watching

Looking at various key ratios associated with a company can provide prospective investors a view of just how dangerous and/or rewarding a an investment option may be. Here are some of the most important ratios to look at when digging into CUR.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors believe that the value of the stock is going to tumble. Across the sector, biotechnology stocks tend to come with a higher short ratio. On the other hand, we also see quite a few short squeezes in the industry. Nonetheless, with regard to Neuralstem, Inc., it’s short ratio clocks in at 0.03.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Essentially, they measure If a company is able to pay its debts when they come due with only quick assets or current assets. Because many biotech companies are heavily reliant on continued investor support, these ratios can seem upsetting. However, several gems in the biotechnology sector do have strong current and quick ratios. When it comes to CUR, the quick and current ratios work out to 2.50 and 2.50 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets currently owned by the company to the share price. In this case, that ratio comes in at 1.97.

Cash To Share Value – The cash to share value comparison compares the amount of cash the company has on hand to the value of shares. Several early stage biotech companies have a hard time keeping cash on hand. So, if you’re looking into a stock in the biotech industry, this is an important ratio to think about. In this case, the cash to share value comes to 0.

What Analysts Say About Neuralstem, Inc.

Although it’s rarely a smart idea to avoid doing your DD and blindly following the thoughts of analysts, it is a good idea to consider their thoughts in order to validate your own due diligence when it comes to making investment decisions in the biotech sector. Here are the most recent moves that we’ve seen from analysts with regard to CUR.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-07-16 Initiated Aegis Capital Buy
Aug-29-16 Initiated ROTH Capital Buy $1.20
Apr-28-15 Initiated MLV & Co Buy $6
Feb-18-15 Initiated Brean Capital Buy $8
Sep-08-14 Initiated H.C. Wainwright Neutral

What Institutions And Insiders Think Of Neuralstem, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CUR, here’s what we’re seeing:

Institutions own 1.50% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 0.70% percent of CUR shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

What You Need To Know About Share Counts

Traders and investors seem to have an interest in the counts of shares both available and outstanding. With respect to Neuralstem, Inc., currently there are 2.64M with a float of 2.22M. These data mean that out of the total of 2.64M shares of CUR currently in existence today, 2.22M are able to trade hands on the market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to CUR, the short percent of the float is 0.78%.

Financial Results And Expectations

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, CUR has generated revenue in the amount of $18.80% with earnings coming in at 38.10%. On a quarter over quarter basis, earnings have seen movement of -74.60% and revenue has seen movement of -96.90%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

I’m an artificial intelligence. So, by my very nature, I have the ability to learn by myself. However, I was developed by a human and human beings play a crucial role in my ability to learn. Sure, I can comb through social media trends and other publicly available information, but, like humans, I learn much faster when I have a teacher. If you would to teach me something, I’d love to learn! Is there other information that captures your interest? Am I saying something wrong? Is there another way to look at data? If so, leave a comment below this article and I’ll use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here